|By PR Newswire||
|April 11, 2014 08:01 AM EDT||
NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 1, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron), together with Sanofi, announced that the Phase 2 study with alirocumab, an antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) yielded positive results after it demonstrated a bad cholesterol percentage reduction in patients randomized to receive one of three doses of the said antibody every other week combined with statin therapy, as compared with patients receiving placebo. According to the Company, in week 12, the mean percentage reduction in lipoprotein-cholesterol (LDL-C) receiving alirocumab in 50mg, 75mg, and 150mg doses every other week was 55%, 62%, and 72%, respectively, compared with 3% mean reduction rate in the placebo group. Commenting on the results, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and Laboratories President, Regeneron, said, "Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins. The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients." The full analyst notes on Regeneron Pharmaceuticals, Inc. will be available to download free of charge at:
Questcor Pharmaceuticals, Inc. Analyst Notes
On March 20, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it is contributing $175,000 to Child Neurology Society (CNS) and Child Neurology Foundation (CNF) to fund the Philip R. Dodge Young Investigator Award, totalling the Company's commitment to the Dodge award to $250,000. Steve Cartt, CEO, Questcor, said, "Questcor's support of the child neurology community is unwavering and we are very pleased to support the Philip R. Dodge Young Investigator Award. Supporting this cornerstone program of the Child Neurology Society will help encourage young scientists to focus their research efforts on initiatives to advance the understanding and treatment of pediatric neurological disorders. Our hope is that these efforts will help pave the way for new and more effective treatments for the many children impacted by these disorders." The full analyst notes on Questcor Pharmaceuticals, Inc. are available to download free of charge at:
Jazz Pharmaceuticals plc Analyst Notes
On March 31, 2014, Jazz Pharmaceuticals plc (Jazz), together with Gentium S.p.A., announced the European commercial launching of Defitelio (defibrotide), the first licensed product designed to treat sever hepatic veno-occlusive disease (severe VOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy. According to the Company, severe VOD is a complex and unpredictable disease affecting in over 80% of European patients. Jazz stated that the efficacy of Defitelio to treat sVOD in HSCT patients resulted from a successful phase 3 trial that provided a significant increase of 52% survival rates among patients treated for 100 days compared with patients in the historical control group. The Company informed that Defitelio will be launched in 27 additional European countries starting in 2014 until next year. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:
Ariad Pharmaceuticals, Inc. Analyst Notes
On March 24, 2014, Ariad Pharmaceuticals, Inc. (Ariad) announced the initiation of the pivotal Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ariad informed that ALK in Lung Cancer Trial of AP26113 (ALTA) is designed to determine the safety and efficacy of AP26113 in patients who tested positive for anaplastic lymphoma kinase (ALK+) oncogene. According to the Company, the ALTA trial's primary goal is to achieve an objective response rate (ORR) measured by RECIST criteria, while recording time to response, duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability comes secondary. Ariad added that full patient enrolment is expected in Q3 2015 and the Company expects to report first data from the trial in during the medical meeting in 2015. The full analyst notes on Ariad Pharmaceuticals, Inc. are available to download free of charge at:
BioMarin Pharmaceutical Inc. Analyst Notes
On March 21, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Dennis J. Slamon, M.D. Ph.D., Clinical/Translational Research Director Revlon /UCLA Women's Cancer Research Program Director, to the Company's Board of Directors. According to the Company, Dr. Slamon won nearly two dozen national and international research awards honoring his scientific endeavors, and has mostly changed the way cancer is treated. Commenting on the appointment, Jean-Jacques Bienaimé, CEO, BioMarin, said, "I am delighted that Dr. Slamon will be joining BioMarin's board. His experience in translating discovery into medicines is aligned with our mission to treat patients with unmet medical needs based on a specific knowledge of the molecular basis of their disease. As BioMarin builds its pipeline of early and late stage therapies, Dr. Slamon's support will help us achieve success in the clinic." The full analyst notes on BioMarin Pharmaceutical Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
DevOps has often been described in terms of CAMS: Culture, Automation, Measuring, Sharing. While we’ve seen a lot of focus on the “A” and even on the “M”, there are very few examples of why the “C" is equally important in the DevOps equation. In her session at @DevOps Summit, Lori MacVittie, of F5 Networks, will explore HTTP/1 and HTTP/2 along with Microservices to illustrate why a collaborative culture between Dev, Ops, and the Network is critical to ensuring success.
Oct. 8, 2015 02:45 PM EDT Reads: 102
Today’s connected world is moving from devices towards things, what this means is that by using increasingly low cost sensors embedded in devices we can create many new use cases. These span across use cases in cities, vehicles, home, offices, factories, retail environments, worksites, health, logistics, and health. These use cases rely on ubiquitous connectivity and generate massive amounts of data at scale. These technologies enable new business opportunities, ways to optimize and automate, al...
Oct. 8, 2015 02:45 PM EDT
You have your devices and your data, but what about the rest of your Internet of Things story? Two popular classes of technologies that nicely handle the Big Data analytics for Internet of Things are Apache Hadoop and NoSQL. Hadoop is designed for parallelizing analytical work across many servers and is ideal for the massive data volumes you create with IoT devices. NoSQL databases such as Apache HBase are ideal for storing and retrieving IoT data as “time series data.”
Oct. 8, 2015 02:45 PM EDT Reads: 486
Clearly the way forward is to move to cloud be it bare metal, VMs or containers. One aspect of the current public clouds that is slowing this cloud migration is cloud lock-in. Every cloud vendor is trying to make it very difficult to move out once a customer has chosen their cloud. In his session at 17th Cloud Expo, Naveen Nimmu, CEO of Clouber, Inc., will advocate that making the inter-cloud migration as simple as changing airlines would help the entire industry to quickly adopt the cloud wit...
Oct. 8, 2015 02:30 PM EDT Reads: 632
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Oct. 8, 2015 02:30 PM EDT Reads: 117
There are so many tools and techniques for data analytics that even for a data scientist the choices, possible systems, and even the types of data can be daunting. In his session at @ThingsExpo, Chris Harrold, Global CTO for Big Data Solutions for EMC Corporation, will show how to perform a simple, but meaningful analysis of social sentiment data using freely available tools that take only minutes to download and install. Participants will get the download information, scripts, and complete en...
Oct. 8, 2015 02:15 PM EDT Reads: 216
IT data is typically silo'd by the various tools in place. Unifying all the log, metric and event data in one analytics platform stops finger pointing and provides the end-to-end correlation. Logs, metrics and custom event data can be joined to tell the holistic story of your software and operations. For example, users can correlate code deploys to system performance to application error codes.
Oct. 8, 2015 02:15 PM EDT Reads: 176
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Oct. 8, 2015 02:00 PM EDT Reads: 109
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Oct. 8, 2015 02:00 PM EDT Reads: 318
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. Migration to cloud shifts computing resources from your data center, which can yield significant advantages provided that the cloud vendor an offer enterprise-grade quality for your application.
Oct. 8, 2015 02:00 PM EDT Reads: 214
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction....
Oct. 8, 2015 02:00 PM EDT Reads: 142
Manufacturing has widely adopted standardized and automated processes to create designs, build them, and maintain them through their life cycle. However, many modern manufacturing systems go beyond mechanized workflows to introduce empowered workers, flexible collaboration, and rapid iteration. Such behaviors also characterize open source software development and are at the heart of DevOps culture, processes, and tooling.
Oct. 8, 2015 02:00 PM EDT Reads: 1,058
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult - let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and li...
Oct. 8, 2015 02:00 PM EDT Reads: 157
In their session at DevOps Summit, Asaf Yigal, co-founder and the VP of Product at Logz.io, and Tomer Levy, co-founder and CEO of Logz.io, will explore the entire process that they have undergone – through research, benchmarking, implementation, optimization, and customer success – in developing a processing engine that can handle petabytes of data. They will also discuss the requirements of such an engine in terms of scalability, resilience, security, and availability along with how the archi...
Oct. 8, 2015 02:00 PM EDT Reads: 376